Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer

Gunduz,Seyda; Mutlu,Hasan; Uysal,Mukremin; Coskun,Hasan  Senol; Bozcuk,Hakan

doi:10.3892/ol.2014.2495

Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer

Authors:
- Seyda Gunduz
- Hasan Mutlu
- Mukremin Uysal
- Hasan Senol Coskun
- Hakan Bozcuk
View Affiliations

Affiliations: Department of Medical Oncology, Akdeniz University Hospital, Antalya 07070, Turkey, Department of Medical Oncology, Afyon Kocatepe University Ahmet Necdet Sezer Research and Practice Hospital, Afyon 3000, Turkey
Published online on: September 3, 2014 https://doi.org/10.3892/ol.2014.2495
Pages: 2249-2252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with cancer are at increased risk of thrombosis. Additionally, an increased mean platelet volume (MPV) has been demonstrated to be associated with thromboembolism. Tyrosine kinase inhibitors (TKIs) may modulate the activation of systemic coagulation in cancer patients, rendering them more susceptible to thromboembolism. The aim of the current study was to investigate the association between antiangiogenic TKIs and MPV. A total of 45 patients with metastatic renal cell carcinoma (RCC), who were treated with TKIs and were patients at the Akdeniz University Hospital and Afyon Kocatepe University Ahmet Necdet Sezer Research and Practice Hospital, were retrospectively reviewed. The results prior to treatment and after three months for the MPV values and platelet levels were evaluated. The MPV values increased following the treatment with TKIs; however, no statistically significant difference was observed between the baseline and three month values (P=0.286). Conversely, a significant decrease was observed in the platelet levels following treatment (P=0.005). Treatment with TKIs in patients with metastatic RCC caused a modest increase in MPV, which is an indicator of thrombocytic reactivity; however, further studies are required to validate these results.

View Figures

View References

1	Thompson CB and Jakubowski JA: The pathophysiology and clinical relevance of platelet heterogeneity. Blood. 72:1–8. 1988.
2	Thompson CB, Jakubowski JA, Quinn PG, Deykin D and Valeri CR: Platelet size and age determine platelet function independently. Blood. 63:1372–1375. 1984.
3	Smith NM, Pathansali R and Bath PM: Platelets and stroke. Vasc Med. 4:165–172. 1999.
4	Endler G, Klimesch A, Sunder-Plassmann H, et al: Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 117:399–404. 2002.
5	O’Malley T, Langhorne P, Elton RA and Stewart C: Platelet size in stroke patients. Stroke. 26:995–999. 1995.
6	Tschoepe D, Roesen P, Esser J, et al: Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 17:433–438. 1991.
7	Mutlu H, Berk V, Karaca H, et al: Treatment regimen with bevacizumab decreases mean platelet volume in patients with metastatic colon cancer. Clin Appl Thromb Hemost. 18:546–548. 2012.
8	Inagaki N, Kibata K, Tamaki T, Shimizu T and Nomura S: Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 83:97–101. 2013.
9	Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 10:145–147. 2004.
10	Cohen RB and Oudard S: Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs. 30:2066–2079. 2012.
11	Elice F, Rodeghiero F, Falanga A and Rickles FR: Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol. 22:115–128. 2009.
12	Kuenen BC, Levi M, Meijers JC, et al: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 22:1500–1505. 2002.
13	Kuenen BC: Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb. 33:13–14. 2003.
14	Nalluri SR, Chu D, Keresztes R, Zhu X and Wu S: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 300:2277–2285. 2008.
15	Choueiri TK, Schutz FA, Je Y, Rosenberg JE and Bellmunt J: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 28:2280–2285. 2010.
16	Greisenegger S, Endler G, Hsieh K, et al: Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke. 35:1688–1691. 2004.
17	Smith NM, Pathansali R and Bath PM: Platelets and stroke. Vasc Med. 4:165–172. 1999.
18	Osada J, Rusak M, Kamocki Z, Dabrowska MI and Kedra B: Platelet activation in patients with advanced gastric cancer. Neoplasma. 57:145–150. 2010.
19	Cho SY, Yang JJ, You E, et al: Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets. 24:375–377. 2012.
20	Mutlu H, Artis TA, Erden A and Akca Z: Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost. 19:331–333. 2013.
21	Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J and Hansen JB: Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost. 8:157–162. 2010.
22	Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 99:1232–1239. 2007.
23	Hambleton J, Skillings J, Kabbinavar F, et al: Safety of low-dose aspirin (ASA) in pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 23:16S(abstr 3554). 2005.
24	Tebbutt NC, Murphy F, Zannino D, et al: Australasian Gastro-Intestinal Trials Group: Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol. 22:1834–1838. 2011.